MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.
Merck’s rival Keytruda gets new US indication.
The FDA has accepted Celgene’s filing for enasidenib.
Roche’s top seller faces rival four years after patent expiry
Antibody-drug conjugate with FDA gets six-month review.
Body unconvinced by clinical data for Venclyxto .
Investment fund kick-starts phase 2 trial in CMML
Imbruvica approved in marginal zone lymphoma.